RTP Mobile Logo
One Year Later: The Practical Application of Research Advances in the Management of Early and Advanced Breast Cancer
Released March 2013

Proceedings from a satellite symposium during the 35th annual San Antonio Breast Cancer Symposium. Including perspectives from Drs Kimberly L Blackwell, Harold J Burstein, George W Sledge Jr, Chris Twelves and Clifford Hudis. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, nurses, surgeons, radiation oncologists and other healthcare practitioners involved in the treatment of early and advanced breast cancer.

    OVERVIEW OF ACTIVITY

    Breast cancer remains the most frequently diagnosed cancer in women, with an estimated 226,870 new cases and 39,510 deaths in the United States in 2012. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

    The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these agents. The indication and utility of these local and systemic therapeutic options are based largely on a number of prognostic and predictive risk factors present within the patient or the tumor at the time of diagnosis. Despite the existence of various evidence- and/or consensus-based guidelines or algorithms that aim to assist oncologists in making treatment decisions, many areas of controversy persist within the academic and community settings. To bridge the gap between research and patient care, these proceedings from a case-based CME symposium during the 35th annual San Antonio Breast Cancer Symposium (SABCS) explore the most significant therapeutic advances since the 2011 SABCS by using the perspectives of leading breast cancer experts and employing a unique strategy centered on actual cases from community-based oncologists to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists formulate up-to-date clinical management strategies.

    LEARNING OBJECTIVES
    • Appropriately use existing and emerging biomarkers to assess risk and individualize therapy for patients with invasive early breast cancer.
    • Implement a long-term clinical plan for the management of early and advanced HER2-positive breast cancer, incorporating existing and emerging targeted treatments.
    • Apply the results of current clinical research to the evidence-based care of patients with triple-negative breast cancer.
    • Assimilate new clinical trial evidence into the therapeutic algorithm for localized and advanced ER-positive, pre- and postmenopausal breast cancer.
    • Demonstrate knowledge of emerging research to support novel chemotherapeutic and nonchemotherapy-based regimens in the adjuvant and metastatic settings, and integrate these findings into best-practice disease management strategies.
    • Recall the results of pivotal trials introducing effective new breast cancer therapeutics, and identify their impact on existing treatment algorithms.
    • Counsel appropriately selected patients about participation in ongoing breast cancer clinical research.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue


    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kimberly L Blackwell, MD

    Professor of Medicine
    Director, Breast Cancer Program
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Eisai Inc, Novartis Pharmaceuticals Corporation; Consulting Agreements: Novartis Pharmaceuticals Corporation, Xcenda; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genomic Health Inc, Novartis Pharmaceuticals Corporation.

    Harold J Burstein, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No real or apparent conflicts of interest to disclose.

    George W Sledge Jr, MD
    Ballve-Lantero Professor of Oncology
    Distinguished Professor of Medicine and Pathology
    Indiana University Simon Cancer Center
    Indiana University School of Medicine
    Indianapolis, Indiana

    Advisory Committee: GlaxoSmithKline.

    Chris Twelves, BMedSci, MBChB, MD

    Professor of Clinical Pharmacology and Oncology
    Head, Clinical Cancer Research Groups
    Leeds Institute of Molecular Medicine and St James’s Institute of Oncology
    Leeds, United Kingdom

    Advisory Committee: Eisai Inc, Roche Laboratories Inc; Speakers Bureau: Eisai Inc.

    Clifford Hudis, MD
    Chief, Breast Cancer Medicine Service
    Solid Tumor Division
    Department of Medicine
    Memorial Sloan-Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    No real or apparent conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Eisai Inc, Genentech BioOncology and Genomic Health Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

Acknowledge and close

Watch video
(WiFi is recommended for best performance):

Introduction – Dr Love
Module 1 –
Dr Blackwell:
HER2-Positive Metastatic Breast Cancer
Module 2 –
Dr Burstein:
Adjuvant Treatment of HER2-Negative BC
Module 3 –
Dr Sledge:
Neo(adjuvant) Anti-HER2 Therapies
Module 4 –
Dr Twelves:
Management of Triple-Negative BC
Module 5 –
Dr Hudis:
ER-Positive, HER2-Negative Metastatic BC